Compare VanEck Video Gaming and eSports ETF (ESPO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Merck & Co., Inc. — how do they compare? VanEck Video Gaming and eSports ETF trades at $97.96, while Merck & Co., Inc. trades at $132.9 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while VanEck Video Gaming and eSports ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $131.84 |
52-Week Low | $85.25 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.97, down 1.64% today, with a bullish technical signal from moving averages and oscillators. Key support lies at $98, with resistance at $100. The stock shows strong momentum indicators, including a 6-day ADX of 55.42 signaling a strong trend. Recent financial data is unavailable, requiring updated SEC filings for fundamental assessment.
The outlook hinges on upcoming earnings to validate growth; risks include market volatility and lack of recent financial disclosures. Analyst sentiment is cautiously optimistic given technical strength, but fundamental clarity is needed for sustained upside.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
